Background/Objectives: Due to the rarity and histological heterogeneity of non-epithelial ovarian cancers (NEOCs), monitoring their reproductive and oncological outcomes is challenging. Therefore, this study aimed to investigate the oncological and reproductive outcomes of patients with NEOCs treated with fertility-sparing surgery over the past 10 years at our tertiary referral university clinic. Methods: This retrospective study included all the NEOC patients diagnosed and treated with fertility-sparing surgery from 2010 to 2019. The patient demographic and clinical characteristics; data regarding the treatment andthe clinical, laboratory, and imaging findings during follow-up; and disease recurrences were recorded. In this study, the recurrence-free survival and the overall survival were the oncological outcomes. The reproductive outcomes were assessed as attempting and achieving pregnancy. Results: This study included 39 patients. The most frequent NEOCs were granulosa cell tumors (53.8%). The majority of the tumors were in the IA or IC1 stage. The initial therapy was generally a unilateral salpingo-oophorectomy (30.8%). Adjuvant chemotherapy was received by 48.7% of the patients. An NEOC recurrence was registered in 25.6% of the patients, mostly during the first two postoperative years. The recurrence-free survival was 76.92%. A regression analysis showed that amore advanced stage of NEOC was the most important predictor of disease recurrence. The overall survival rate was 87.2%, with a mean time to an adverse outcome of 23.01 +/−10.68 months. The regression analysis showed that better survival depended mostly on not having disease recurrence. After treatment, ten patients tried to conceive and seven succeeded. All the children were in good condition upon birth. Conclusions: Fertility-sparing treatment for NEOCs was proven as a safe and successful option in terms of both oncological and reproductive outcomes.
背景/目的：鉴于非上皮性卵巢癌（NEOCs）的罕见性和组织学异质性，监测其生殖与肿瘤学结局具有挑战性。因此，本研究旨在探讨过去十年间在我院三级转诊大学诊所接受保留生育功能手术治疗的非上皮性卵巢癌患者的肿瘤学及生殖结局。方法：本回顾性研究纳入了2010年至2019年间所有经诊断并接受保留生育功能手术治疗的NEOC患者。记录了患者的人口统计学和临床特征、治疗相关数据、随访期间的临床、实验室及影像学检查结果，以及疾病复发情况。本研究以无复发生存期和总生存期作为肿瘤学结局指标，生殖结局则通过尝试妊娠和成功妊娠进行评估。结果：本研究共纳入39例患者。最常见的NEOC类型为颗粒细胞瘤（53.8%）。多数肿瘤处于IA或IC1期。初始治疗主要为单侧输卵管卵巢切除术（30.8%）。48.7%的患者接受了辅助化疗。25.6%的患者出现NEOC复发，多数发生在术后前两年内。无复发生存率为76.92%。回归分析显示，NEOC分期较晚是疾病复发最重要的预测因素。总生存率为87.2%，平均至不良结局时间为23.01±10.68个月。回归分析表明，较好的生存状况主要取决于未出现疾病复发。治疗后，10例患者尝试妊娠，其中7例成功。所有新生儿出生时状况良好。结论：对于非上皮性卵巢癌，保留生育功能的治疗在肿瘤学结局和生殖结局方面均被证明是安全且成功的治疗选择。
肿瘤(癌症)患者之家